Caduet Related Published Studies
Well-designed clinical trials related to Caduet (Amlodipine / Atorvastatin)
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. [2010.05.06]
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. [2010]
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV
risk burden using amlodipine/atorvastatin single-pill therapy in treated
hypertensive participants in a randomized controlled trial. [2010]
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. [2005.01.15]
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. [2004.09]
Well-designed clinical trials possibly related to Caduet (Amlodipine / Atorvastatin)
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. [2011.04]
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. [2009.01]
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. [2001.06]
Other research related to Caduet (Amlodipine / Atorvastatin)
Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. [2011.08.01]
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. [2011.08]
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. [2011]
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. [2009.10]
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. [2009.08]
ADDITIVE BENEFICIAL EFFECTS OF AMLODIPINE AND ATORVASTATIN IN REVERSING ADVANCED CARDIAC HYPERTROPHY IN ELDERLY SPONTANEOUSLY HYPERTENSIVE RATS. [2009.04.27]
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). [2009.03]
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. [2008.01]
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. [2008]
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. [2008]
A single-pill combination of amlodipine besylate and atorvastatin calcium (update). [2007.03]
Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. [2006.09]
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). [2006.06.16]
A single-pill combination of amlodipine besylate and atorvastatin calcium. [2006.03]
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. [2005.07]
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). [2005.05]
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. [2004.09]
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. [2004.02]
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. [2003.09]
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. [2003.07]
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. [2002.09]
Other possibly related research studies
[First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: the ASCOT-BPLA results] [2005.10]
A rationale for combination therapy in risk factor management: a mechanistic perspective. [2005.12]
Interactions between grapefruit juice and cardiovascular drugs. [2004]
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. [2003.11]
Pharmacotherapy for dyslipidaemia--current therapies and future agents. [2003.11]
Gateways to clinical trials. [2002.10]
Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes. [2002.06]
Gateways to Clinical Trials. June 2002. [2002.06]
[An overview of hypertension studies with calcium antagonists] [1999.05.20]
Fixed-dose combination therapy with statins : strengths, limitations, and clinical and regulatory considerations. [2008]
Concurrent use of statins and amiodarone. [2009.05]
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. [2010]
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. [2010.06]
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. [2010.06.17]
|
